BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 19087914)

  • 1. [Gastrointestinal cytomegalovirus infections in organ transplant patients].
    Péter A; Telkes G; Varga M; Járay J
    Orv Hetil; 2008 Dec; 149(52):2463-70. PubMed ID: 19087914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
    Torres-Madriz G; Boucher HW
    Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytomegalovirus infection in transplant recipients].
    Gondo H
    Nihon Rinsho; 1998 Jan; 56(1):173-8. PubMed ID: 9465685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus infection following stem cell transplantation.
    Einsele H; Hebart H
    Haematologica; 1999 Jun; 84 Suppl EHA-4():46-9. PubMed ID: 10907466
    [No Abstract]   [Full Text] [Related]  

  • 5. Small bowel transplantation complicated by cytomegalovirus tissue invasive disease without viremia.
    Avsar Y; Cicinnati VR; Kabar I; Wolters H; Anthoni C; Schmidt HH; Beckebaum S
    J Clin Virol; 2014 Jun; 60(2):177-80. PubMed ID: 24703746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation.
    Zaia JA
    Bone Marrow Transplant; 2002 Apr; 29(8):633-8. PubMed ID: 12180106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients.
    Razonable RR
    Infect Dis Clin North Am; 2013 Jun; 27(2):317-42. PubMed ID: 23714343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus detected in the upper gastrointestinal tract parallel with CMV-antigenemia in liver transplant patients.
    Halme L; Höckerstedt K; Salmela K; Lautenschlager I
    Transplant Proc; 1999; 31(1-2):487. PubMed ID: 10083203
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients.
    Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR
    Am J Transplant; 2010 Jan; 10(1):157-61. PubMed ID: 19889123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.
    Boeckh M; Nichols WG; Papanicolaou G; Rubin R; Wingard JR; Zaia J
    Biol Blood Marrow Transplant; 2003 Sep; 9(9):543-58. PubMed ID: 14506657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver and intestinal transplantation.
    Tzakis AG
    Transpl Infect Dis; 2001; 3 Suppl 2():35-9. PubMed ID: 11926748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal cytomegalovirus disease in the immunocompromised patient.
    Baroco AL; Oldfield EC
    Curr Gastroenterol Rep; 2008 Aug; 10(4):409-16. PubMed ID: 18627655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant recipient.
    Ketteler M; Preuschof L; Mertz A; Stöffler-Meilicke M; Schäfer H; Distler A; Offermann G
    Clin Nephrol; 2000 Nov; 54(5):418-24. PubMed ID: 11105806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
    Asberg A; Rollag H; Hartmann A
    Expert Opin Pharmacother; 2010 May; 11(7):1159-66. PubMed ID: 20367273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
    Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
    Chakrabarti S; Collingham KE; Osman H; Fegan CD; Milligan DW
    Bone Marrow Transplant; 2001 Nov; 28(9):879-81. PubMed ID: 11781649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.
    Razonable RR; Humar A
    Clin Transplant; 2019 Sep; 33(9):e13512. PubMed ID: 30817026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
    Singh N
    Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.